Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 14, H.C. Wainwright lowered its price target on Nurix Therapeutics from $34.00 to $33.00, while reaffirming its Buy rating after the company’s Q3 2025 earnings. Nurix reported a net loss of $1.03 per share, wider than the expected $0.68, and generated $7.9 million in revenue—well below the projected $30 million.
Copyright: dolgachov / 123RF Stock Photo
Operating expenses were higher than anticipated, with R&D costs at $86.1 million. Despite the miss, Nurix ended the quarter with $428.8 million in cash, which H.C. Wainwright believes it will fund operations into early 2027. The revised price target reflects expectations of continued cost pressure, but the firm remains optimistic about the company’s long-term prospects.
Nurix Therapeutics, Inc. is a biopharmaceutical company that discovers and develops targeted protein degradation (TPD) medicines to treat cancer and immune disorders by modulating the levels of specific proteins within cells.
READ NEXT: Top 10 Stocks to Buy As Gold Rallies and 13 Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates.
This article is originally published at Insider Monkey.
